SCHEMBL3667221

SCHEMBL3667221

CC(O)(c1ccccc1)c1cn(-c2ccc3[nH]ncc3c2)nn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.75
GSK3B P49841 11/20 0.75
AURKB Q96GD4 6/20 0.75
CDK5 Q00535 5/20 0.75
DYRK1A Q13627 5/20 0.75
PIM1 P11309 4/20 0.75
AURKA O14965 4/20 0.75
PRKACA P17612 4/20 0.75
GSK3A P49840 4/20 0.75
PRKAA1 Q13131 4/20 0.75
ROCK1 Q13464 4/20 0.75
RPS6KA3 P51812 3/20 0.75
DAPK3 O43293 3/20 0.75
LIMK1 P53667 2/20 0.75
FLT1 P17948 2/20 0.75
KDR P35968 2/20 0.75
CLK2 P49760 2/20 0.75
CLK4 Q9HAZ1 2/20 0.75
DYRK1B Q9Y463 2/20 0.75
FGFR1 P11362 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285308 0.86 JAK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL2191690 0.72 P2RX7 (0.50) KDM1A
SCHEMBL3667547 0.72 JAK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3665013 0.71 JAK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3667117 0.70 JAK2 (0.70) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3667820 0.70 ROCK2 (0.71) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3667957 0.70 ROCK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL4293081 0.69 JAK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3670472 0.69 ROCK2 (0.69) JAK2GSK3BAURKBCDK5DYRK1A
SCHEMBL3666181 0.68 ROCK2 (1.00) JAK2GSK3BAURKBCDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 JAK2 102/4885GSK3B 1/4885AURKB 125/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 JAK2 102/4885GSK3B 1/4885AURKB 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.